<![CDATA[Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer]]>

Phase 2IvonescimabEnfortumab vedotinPembrolizumabNeutral

AI Analysis

Summary

Developers initiated a phase 2/3 trial evaluating enfortumab vedotin combined with ivonescimab or pembrolizumab as first-line treatment for locally advanced/metastatic bladder cancer.

Clinical Trial Data

Phase

2/3

Importance:5/10

Sentiment:

0.20

Bladder cancerImmunotherapyPhase 2/3 trialFrontline therapyClinical development

Related Companies

$ALPMY

Read the original article

Published by Cancer Network on August 6, 2026 4:00 PM

Read Original